IGCS19-0266

79 PRE-BRACHYTHERAPY MAGNETIC RESONANCE-BASED 3D TUMOR VOLUME EVALUATION FOR OUTCOME PREDICTION IN CERVICAL CANCER PATIENTS TREATED WITH DEFINITIVE CHEMORADIATION

¹C El Khoury*, ²D Atallah, ³J Naba, ³A Nassar, ²M Moubarak, ¹F Azoury, ¹T Felefly, ¹J El Barouky, ¹R Sayah, ¹D Nasr, ⁴G Chahine, ¹E Nasr. ¹University of Saint Joseph, Hotel Dieu de France – Department of Radiation Oncology, Beirut, Lebanon; ²University of Saint Joseph, Hotel Dieu de France – Department of Gynecology – Division of Gynecologic Oncology, Beirut, Lebanon; ³University of Saint Joseph, School of Medicine, Beirut, Lebanon; ⁴University of Saint Joseph, Hotel Dieu de France – Department of Medical Oncology, Beirut, Lebanon

10.1136/ijgc-2019-IGCS.79

Objectives To report the impact on survival of residual tumor volume (RTV) prior to brachytherapy (BT) initiation determined by magnetic resonance imaging (MRI) in patients treated for locally advanced cervical cancer with definitive chemoradiotherapy (CRT).

Methods MRI examinations were prospectively performed in patients with advanced cervical cancer (Stages IB2-IVA) after CRT completion and prior to BT initiation. RTV was delineated on each T2-weighted slice and volumetry was derived on the treatment planning system. All patients received external beam radiation (EBRT) with concomitant Cisplatin followed by volume-based BT planning. Cumulative EBRT and BT doses were calculated as the total equivalent dose in 2 Gy fractions (EQD2). Potential prognostic factors were selected based on non-parametric tests and then analyzed for survival with a Cox regression model.

Results Median post-therapy follow-up was 27.4 months (range, 3–57.8). Thirty-seven patients were included. According to the FIGO classification, 8% were stage IB, 75% stage II, 11% stage III, and 6% stage IV. Overall survival was 86.5%. Of the patients evaluated, 29.7% had complete remission on pre-BT MRI and 18.9% were considered having local failure or distant disease. At bivariate analysis, RTV >2 mL, D90 CTV-HR <84 Gy and excessive treatment time were all predictors of poor overall survival. At multivariate regression analysis, only RTV persisted as a significant prognostic factor with survival rates of 95.8% and 69.2% for pre-BT RTV ≤2 mL and >2 mL respectively (p=0.005).

Conclusions Our preliminary data suggest that pre-BT RTV >2 mL is a predictor of poor survival.

IGCS19-0195

80 SMARCA4 INACTIVATION DEFINES A SUBSET OF UNDIFFERENTIATED UTERINE SARCOMAS WITH RHABDOID AND SMALL CELL FEATURES AND GERMLINE MUTATION ASSOCIATION

¹D Lin*, ²J Allen, ³J Hecht, ¹J Killian, ¹N Ngo, ¹C Edgerly, ¹E Severson, ⁴S Ali, ²R Erlich, ¹S Ramkissoon, ¹JA Vergilio, ¹J Ross, ¹J Elvin. ¹Foundation Medicine, Pathology, Cambridge, USA; ²Foundation Medicine, Biomedical Informatics, Cambridge, USA; ³Beth Israel Deaconess Medical Center, Pathology, Boston, USA; ⁴Foundation Medicine, Clinical Development, Cambridge, USA

10.1136/ijgc-2019-IGCS.80

Objectives A rare subset of aggressive SMARCA4-deficient uterine sarcomas (SMARCA4-DUS) has been recently proposed,

with only a limited number of cases having been previously described. Since potential targeted therapies exist for SMARCA4-deficient tumors, we sought to validate and expand the clinicopathological and molecular features of SMARCA4-DUS.

Methods A retrospective database search of a large, CLIA-certified and CAP-accredited, reference molecular laboratory was performed for clinically advanced uterine sarcomas with genomic profiles that contained SMARCA4 mutations. Clinicopathological data were extracted from patient records. Morphological and molecular features were centrally reviewed.

Results Here, we identify and describe the clinicopathological and genomic features of 17 additional cases of SMARCA4-DUS. Median patient age was 51 years (range 33–70). Most tumors were aggressive with distant metastasis. SMARCA4-DUS demonstrated predominantly rhabdoid or large epithelioid cells with abundant cytoplasm, but also had varying degrees of small cell and spindle cell morphology. Tumors were microsatellite stable and exhibited no other or only few co-occurring genomic alterations by comprehensive genomic profiling. We discovered one patient, who developed SMARCA4-DUS at age of 55, had a germline SMARCA4 mutation, whose daughter had previously died of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), at the age of 32.

Conclusions Our data support the notion that SMARCA4 inactivation is the driver oncogenic event of a morphologically and molecularly distinct form of uterine sarcoma. Identification of SMARCA4-DUS may be clinically important due to their aggressive behavior, germline association and emerging targeted therapies.

Poster Discussion with the Professor Station 2

IGCS19-0473

81 ATTITUDE TOWARDS AND FACTORS AFFECTING UPTAKE OF POPULATION BASED BRCA TESTING IN ASHKENAZI JEWS: A COHORT STUDY

¹R Manchanda*, ²M Burnell, ¹F Gaba, ³S Sanderson, ⁴K Loggenberg, ⁵S Gessler, ³J Wardle, ⁶L Side, ⁵R Desai, ⁷A Brady, ⁸H Dorkins, ⁹Y Wallis, ¹⁰C Chapman, ¹¹C Jacobs, ¹²I Tomlinson, ¹³U Beller, ²U Menon, ¹⁴I Jacobs. ¹Queen Mary University of London and Barts Health NHS Trust, Barts Cancer Institute, London, UK; ²University College London, MRC Clinical Trials Unit, London, UK; ³University College London, Behavioral Sciences Unit- Department of Epidemiology and Public Health, London, UK; ⁴Great Ormond Street Hospital, North East Thames Regional Genetics Service, London, UK; ⁵University College London, Department of Womens Cancer, London, UK; ⁶University Hospital Southampton NHS Foundation Trust, Clinical Genetics, Southampton, UK; ⁷Northwick Park Hospital, Dept Clinical Genetics- North West Thames Regional Genetics Unit, London, UK; ⁸University of Oxford, St Peter's College, Oxford, UK; ⁹Birmingham Women's NHS Foundation Trust, West Midlands Regional Genetics Laboratory, Birmingham, UK; ¹⁰Birmingham Women's NHS Foundation Trust, Dept Clinical Genetics- West Midlands Regional Genetics Service, Birmingham, UK; ¹¹University of Technology Sydney, Genetics, Sydney, Australia; ¹²University of Birmingham, Institute of Cancer and Genomic Sciences, Birmingham, UK; ¹³Shaare Zedek Medical Center, Department of Gynaecology, Jerusalem, Israel; ¹⁴University of New South Wales, Chancellery Building, Sydney, Australia

10.1136/ijgc-2019-IGCS.81

Objectives To evaluate the factors affecting interest, intention, uptake, and attitude towards unselected population-based BRCA-testing in the Ashkenazi Jewish (AJ) population.

Methods Design: Cohort-study set within recruitment to the GCaPPS-trial (ISRCTN73338115).

AJ women/men >18-years, from the North-London AJ-population were recruited through self-referral. AJ-women/men underwent pre-test counselling for *BRCA*-testing through recruitment clinics (clusters). Consenting individuals provided blood-sample for *BRCA*-testing. Socio-demographic/family-history/knowledge/psychological well-being data along-with benefits/risks/cultural-influences (18-item-questionnaire measuring 'attitude') were collected.

4-item likert-scales analysed initial 'interest' and 'intention-to-test' pre-counselling.

Uni-&-multivariable logistic-regression-models evaluated factors affecting uptake/interest/intention-to undergo *BRCA*-testing. Statistical inference was based on cluster robust standard-errors and joint Wald-tests for significance. Item-Response-Theory and graded-response-models modelled responses to 18-item questionnaire.

Main Outcome Measures: Interest, intention, uptake, attitude towards *BRCA*-testing

Results 935 AJ women (67%) and men (33%) underwent pre-test genetic-counselling (mean-age=53.8(S.D=15.02) years). Pre-counselling 96% expressed interest but 60% had clear intention-to undergo *BRCA*-testing. Subsequently 88% opted for *BRCA*-testing. *BRCA*-related knowledge ($p=0.013$) and degree-level education($p=0.01$) were positively and negatively (respectively) associated with intention-to-test. Being married/cohabiting had four-fold higher-odds for *BRCA*-testing uptake ($p=0.009$). Perceived benefits were associated with higher pre-counselling odds for interest and intention-to undergo *BRCA*-testing. Reduced uncertainty/reassurance were the most important factors contributing to decision-making. Increased importance/concern towards risks/limitations (confidentiality/insurance/emotional-impact/inability to prevent cancer/marriage-ability/ethnic-focus/stigmatization) were significantly associated with lower-odds of uptake-of *BRCA*-testing, and discriminated between acceptors and decliners. Having children had stronger ($p=0.005$) while male-gender/degree-level-education ($p=0.001$) had weaker, attitudes towards *BRCA*-testing.

Conclusions *BRCA* testing in the AJ population has high acceptability. Pre-test counselling increases awareness of disadvantages/limitations of *BRCA*-testing, influencing the final cost-benefit perception and decision-making on undergoing testing.

IGCS19-0493

82 IDENTIFICATION OF NEOANTIGENS FROM NON-PRIMARY TUMOR TISSUE IN PATIENTS WITH RECURRENT OVARIAN CANCER BY SEQUENCING AND SUBSEQUENT HLA LIGAND MASS SPECTROMETRY

¹R O'Cearbhaill*, ²M Klatt, ²SS Mun, ²T Korontsvit, ³N Socci, ²S Guzman, ⁴M Mattar, ⁵O Zivanovic, ²T Dao. ¹Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, Medicine, New York, USA; ²Sloan Kettering Institute, Molecular Pharmacology, New York, USA; ³Memorial Sloan Kettering Cancer Center, Bioinformatics Core, New York, USA; ⁴Sloan Kettering Institute, Clinical Research, New York, USA; ⁵Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, Gynecologic Surgical Oncology, New York, USA

10.1136/ijgc-2019-IGCS.82

Objectives Adoptive transfer of autologous Tcells specifically targeting neoepitopes derived from tumor mutations has

achieved responses in melanoma and other cancers. We sought to identify ovarian cancer neoepitopes.

Methods We collected tumor, blood and ascites specimens from ovarian cancer patients. We combined mass spectrometry analysis of MHC class1 peptidomes with parallel sequencing of whole exome and RNA of cancer cells, to identify neoepitopes. Missense mutations were identified by whole exome sequencing and epitopes confirmed by mass spectrometry from ascites. We selected peptides predicted to have high binding affinity to HLA-A*02:01, for *in vitro* Tcell priming. We first validated the immunogenicity of these peptides for priming Tcells with synthesized peptides in healthy HLA-A*02:01+ donors.

Results 32 missense mutations were identified in patient's ascites. 7 epitopes were confirmed by mass spectroscopy; 5 were predicted to have high binding affinity to HLA-A*02:01. 3/5 epitopes induced peptide-specific Tcell responses not cross-reactive with native sequences. However, these 3 peptides failed to induce autologous peptide-specific Tcell response in TILs to patient's ascites, nor to autologous tumor cells, suggesting immunosuppression. Interestingly, when autologous tumor cells were pre-treated with IFN-gamma, Tcell responses against tumor cells were observed.

Conclusions We demonstrated effective T cell responses against tumor neoantigens, is not only dependent on stimulation of Tcells, but also on efficient epitope processing and presentation on cell surface. While efforts have been focused on activation of Tcell responses, such as immune checkpoint blockade, our study suggests that strategies to modulate tumor cells to efficiently present neoepitopes should be considered for successful immunotherapy against neoantigens.

IGCS19-0587

83 IMPACT OF INTRODUCING EXTENSIVE SURGICAL PROCEDURES TO CYTOREDUCTIVE SURGERY (CRS) IN ADVANCED EPITHELIAL OVARIAN CANCER (EOC) ON RATE OF COMPLETE DEBULKING (CD) AND SURVIVAL

¹M Seoud*, ¹A El Housseini, ¹I Jaafar, ¹K Hamed, ¹R Abdallah, ¹A Khalil, ²F Jamali. ¹American University of Beirut Medical Center, Obstetrics and Gynecology, Beirut, Lebanon; ²American University of Beirut Medical Center, General Surgery, Beirut, Lebanon

10.1136/ijgc-2019-IGCS.83

Objectives To asses the impact of extensive procedures (Diaphragmatic resection, large and small bowel resection, complete peritonectomy, complete omentectomy, paraaortic lymph node dissection, splenectomy, resection of all visible disease) in CRS on the rate of CD, progression free (PFS), and overall survival (OS) in patients with advanced EOC.

Methods Patients undergoing CRS between 2002–2018 were divided into group#1(2002–2008), and group#2 (2009–2018). Demographic and operative information were retrospectively reviewed.

Results 204 patient with EOC (IIIC-IV) underwent CRS between 2002–2018. The number of CRS as well as performing extensive procedures (figure1A) has significantly increased over the whole period (72 in group1 vs 132 in group2: p -value<0.001), and this coincided with a significant increase in the CD rate from 50% to 80% (p -value<0.001) (figure 1A). In stage IIIC, median PFS was significantly higher in group#2 versus group#1 (22 months, 95%CI 16.80–27.19 and 23